New triple-drug attack targets tough lymphoma
NCT ID NCT07548255
First seen Apr 25, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This early-phase study tests a combination of three drugs (sonrotoclax, zanubrutinib, and obinutuzumab) as a first treatment for people newly diagnosed with an aggressive form of mantle cell lymphoma. About 28 adults with high-risk features will receive the therapy to see how many achieve complete remission. The goal is to improve disease control without using chemotherapy right away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERMEDIATE-TO-HIGH-RISK MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.